{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:59:06Z","timestamp":1790139546626,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>High\u2010dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is widely used in patients with diffuse large B\u2010cell lymphoma. HDCT\/ASCT is associated with increased morbidity in elderly\/unfit patients. We retrospectively evaluated the use of reduced intensity conditioning in DLBCL patients. Our study included 146 patients aged 60\u2009years and older treated at our institution between 2005 and 2019; 86 patients received standard intensity conditioning (SI group) with BEAM or TEAM (BCNU or thiotepa, etoposide, cytarabine, melphalan). Sixty patients received reduced intensity high\u2010dose conditioning (RI group) with BM (BCNU, melphalan, 43.3%), TM (thiotepa, melphalan, 16.7%), BCNU or busulfan thiotepa (38.4%), or bendamustine melphalan (1.7%). Median follow\u2010up was 62.4\u2009months. We observed comparable toxicities in the SI and RI groups. The cumulative incidence of relapse at 3\u2009years was higher in the RI group (30.8% vs. 23.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.034). There was no difference in nonrelapse mortality (NRM). In univariate analyses, SI vs. RI conditioning resulted in superior progression\u2010free survival (PFS) (HR 1.80 CI 1.11\u20132.92, <jats:italic>p<\/jats:italic>\u2009=\u20090.017) but not in superior overall survival (OS) (HR 1.48 CI 0.86\u20132.56, <jats:italic>p<\/jats:italic>\u2009=\u20090.152). On multivariate analysis, we observed no difference in PFS (HR 0.74 CI 0.40\u20131.38, <jats:italic>p<\/jats:italic>\u2009=\u20090.345) and a trend toward better OS with RI conditioning (HR 0.45 CI 0.22\u20130.94, <jats:italic>p<\/jats:italic>\u2009=\u20090.032). Age 60\u201369 versus \u2265\u200970\u2009years and remission prior to ASCT were the only factors predicting better PFS. Factors associated with better OS were RI conditioning, age 60\u201369 versus \u2265\u200970\u2009years, ECOG 0 versus \u2265\u20091 performance status, bulky disease, and prior lines 1 versus \u2265\u20092. In conclusion, RI conditioning prior to ASCT may be feasible in elderly patients and led to a comparable outcome when corrected for several significant confounders.<\/jats:p>","DOI":"10.1111\/ejh.14320","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T10:05:16Z","timestamp":1728554716000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly <scp>DLBCL<\/scp> Patients"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-1599","authenticated-orcid":false,"given":"Tim","family":"Str\u00fc\u00dfmann","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hermes","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Faculty of Medicine, University Medical Center University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jes\u00fas","family":"Duque\u2010Afonso","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation Medical Center \u2010 University of Freiburg, Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.08.019"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.025"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0499"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04373-z"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.1001987"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.06.007"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170752"},{"key":"e_1_2_11_14_1","article-title":"High\u2010Dose Chemotherapy With Autologous Stem Cell Transplantation in the First Line Treatment of Aggressive Non\u2010Hodgkin Lymphoma (NHL) in Adults","volume":"2008","author":"Greb A.","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32464"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301077"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18280"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25558"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9866"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031770"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004863"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.208"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.06.011"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5473-z"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2311-4"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.01.002"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2004"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.06.019"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:02:08Z","timestamp":1757322128000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/ejh.14320"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14320","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"2024-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}